Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis.
Aim IMpower133 was designed with 4 cycles of chemoimmunotherapy with atezolizumab, unlike many other studies permitted 6-cycle induction. This study aimed to compare the efficacy and safety of a 4-cycle regimen with an extended 6-cycle regimen of carboplatin, etoposide, and atezolizumab in the first...
| Publicado en: | Oncologist Vol. 31; no. 4; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
Apr2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192902233&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192902233 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10837159 IJ7 jtl: Oncologist issn: 10837159 maglogo: N pubinfo: dt: Apr2026 vid: 31 iid: 4 pid: 622 pub: Oxford University Press / USA artinfo: ui: 192902233 192902233 192902233 10.1093/oncolo/oyag092 192902233 ppf: 1 ppct: 11 formats: tig: atl: Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis. aug: au: Güzel, Halil Göksel Salim, Derya Kıvrak Kılıçkap, Saadettin Kemal, Yasemin Akosman, Cengiz Köseoğlu, Çağlar Coşkun, Alper Orman, Seval Efil, Safa Can Baş, Onur affil: Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, 07000, Turkey sug: subj: Neoplasm Staging Lung Neoplasms Drug Therapy Chemotherapy, Cancer Programmed Cell Death Ligand 1 Antagonists and Inhibitors Carboplatin Administration and Dosage Etoposide Administration and Dosage Antineoplastic Agents, Combined Administration and Dosage Treatment Outcomes Evaluation Human Turkiye Male Female Adult Middle Age Aged Aged, 80 and Over Retrospective Design Record Review Multicenter Studies Progression-Free Survival Overall Survival Neoplasm Metastasis Risk Factors Brain Neoplasms Risk Factors Disease Progression Risk Factors Antineoplastic Agents, Combined Adverse Effects Descriptive Statistics Data Analysis Software Chi Square Test Fisher's Exact Test Survival Analysis Kaplan-Meier Estimator Univariate Statistics Multivariate Analysis Cox Proportional Hazards Model Regression Confidence Intervals Age Factors Functional Status Physical Performance Clinical Assessment Tools Scales Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Male Female ab: Aim IMpower133 was designed with 4 cycles of chemoimmunotherapy with atezolizumab, unlike many other studies permitted 6-cycle induction. This study aimed to compare the efficacy and safety of a 4-cycle regimen with an extended 6-cycle regimen of carboplatin, etoposide, and atezolizumab in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Methods This retrospective multicenter study was conducted across 13 oncology centers in Turkey. A total of 181 patients with ES-SCLC who received first-line treatment with chemotherapy plus atezolizumab were analyzed and grouped into those receiving 4 cycles (n = 101) and 6 cycles (n = 80) of treatment. Results The median follow-up time was 20.9 months. The objective response rates were similar between the 4- and 6-cycle groups (79.2% vs 78.8%, P = .940). The disease control rates were also comparable (84.2% vs 86.3%, P = .940). The median progression-free survival (PFS) was 6.3 months in the 4-cycle and 8.1 months in the 6-cycle group (P = .357). The median overall survival (OS) was 16.6 months for the 4-cycle and 13.6 months for the 6-cycle group (P = .583). Intracranial progression was higher in the 4-cycle group (50.0% vs 25.5%, P = .007). Immune-related adverse events were similar between the groups. Conclusion This is one of the largest real-world datasets comparing the efficacy and safety of 4 versus 6 cycles of induction chemoimmunotherapy. Although there were no significant improvements in PFS or OS, the 6-cycle regimen was associated with a lower observed rate of intracranial progression, predominantly among patients without baseline brain metastases. Further studies are needed to identify this subject in future. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|